Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

HbA1c and Diabetic Ketoacidosis POC Analyzers to Be Demonstrated at ArabHealth

By Labmedica International staff writers
Posted on 03 Jan 2014
Print article
Image: The EKF Quo-Lab HbA1c Analyzer (Photo courtesy of EKF Diagnostics).
Image: The EKF Quo-Lab HbA1c Analyzer (Photo courtesy of EKF Diagnostics).
A leader in in-vitro diagnostics will exhibit in an upcoming medical congress two point-of-care (POC) analyzers for the rapid assessment of diabetes and related conditions.

The Quo-Lab HbA1c analyzer and the STAT-Site M β-HB by EKF Diagnostics (EKF; Cardiff, UK) will be demonstrated at the Welsh stand during the ArabHealth healthcare exhibition and medical congress, which will take place January 27–30, 2014, at the International Convention and Exhibition Center in Dubai (UAE).

HbA1c monitoring is increasingly used in the detection and management of diabetes: Quo-Lab provides highly accurate, affordable, and easy-to-use technology, which uses only 4 µL of venous or finger prick blood to deliver results within four minutes. The analyzer, which was launched mid-2013, has had a good reception, with nearly 1,300 being sold globally to date. The Quo-Lab analyzer is designed to meet the needs of GP surgeries, clinics, and laboratories in emerging economies, where diabetes has become a growing public health issue.

The second analyzer to be demonstrated, the STAT-Site M β-HB, is a quantitative strip-based test for ß-Hydroxybutyrate (ß-HB). The device provides quick and easy assessment of diabetic ketoacidosis (DKA), delivers results in less than 80 seconds, and it is CE marked.

Using the STAT-Site M ß-HB, the presence and degree of ketosis can be assessed at POC by accurately measuring blood levels of ß-HB, which accounts for 78% of the three ketone bodies, from just 10 µL of serum or plasma. This provides useful information to deliver quality care when monitoring DKA in newly diagnosed patients, while also reducing time and costs in an emergency room setting.

Related Links:

EKF Diagnostics



Print article

Channels

Clinical Chemistry

view channel

New Approach Improves Identification of Women at High Risk of Preeclampsia

A new meta-analysis examining 92 cohort studies involving over 25 million pregnancies has provided an unprecedented understanding of risk factors for preeclampsia—some risk factors being strong enough to warrant that a pregnant woman starts on prophylactic treatment with acetylsalicylic acid (ASA) when she has only one.... Read more

Genetic Tests

view channel

Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis

Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases. MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression... Read more

Pathology

view channel

Liver Cancer May Be Diagnosed from Altered Sugar Metabolism

Altered gene expression that causes cancerous cells to metabolize fructose differently from healthy cells could be a significant new biomarker for diagnosing liver cancer. Dietary fructose is primarily metabolized in the liver and it has now been demonstrated that, compared with normal hepatocytes, hepatocellular carcinoma... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.